Baseline angiotensin receptor blocker–based regimens and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer
Background Angiotensin receptor blockers (ARBs) act on a pathway implicated in stromal immune suppression. We examined the association between baseline ARB-based treatment and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer (NSCLC). Methods This single-center retrospective cohort included 312 patients who started a PD-1 inhibitor plus platinum-doublet chemotherapy during 2021–2024. Patients receiving an ARB-based regimen (n = 142) were compared with those receiving a dihydropyridine calcium channel blocker (CCB) regimen without renin–angiotensin–aldosterone system (RAAS) inhibitors (n = 170). Baseline exposure required continuous drug-class use for at least 30 days before treatment initiation. The primary endpoint was progression-free survival (PFS), analyzed using multivariable Cox regression. Sensitivity analyses included propensity score overlap weighting. Objective response rate (ORR), overall survival (OS), early blood pressure and renal function, and adverse events were assessed as exploratory outcomes. Results At a median follow-up of 26.9 months, median PFS was 13.1 months in the ARB-based group and 8.1 months in the CCB comparator group (adjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.56–0.95; P = 0.019). The overlap-weighted HR was 0.75 (95% CI, 0.57–0.99). Objective response rates were 61.3% and 48.2%, respectively (unadjusted P = 0.023; adjusted odds ratio, 1.55; 95% CI, 0.96–2.50; P = 0.072). Median OS was 29.7 versus 23.6 months (adjusted HR, 0.73; 95% CI, 0.53–1.02; P = 0.063). Adjusted week-12 blood pressure and renal function did not differ significantly between groups. Grade ≥3 treatment-emergent adverse events occurred in 28.2% and 27.6% of patients. Conclusion A baseline ARB-based regimen was associated with longer PFS than a CCB regimen without RAAS inhibitors in this hypertensive NSCLC cohort. The adjusted ORR and OS comparisons did not reach statistical significance. These findings support prospective evaluation of ARBs alongside first-line chemoimmunotherapy.
Authors
- Cai Yue (ORCID: https://orcid.org/0000-0001-5754-0225)
- Kai Sun (ORCID: https://orcid.org/0000-0002-1929-0453)
- Fu Yi (ORCID: https://orcid.org/0009-0002-2966-5906)
- Ziyu Jin (ORCID: https://orcid.org/0009-0002-7620-7342)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fphar.2026.2008179
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00